Global InformationJaktinib information
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| DrugBank |
|
Jaktinib is a janus kinase inhibitor under development for myelofibrosis.[1][2] It is a deuterated-drug analog of momelotinib.[1]
- ^ a b Zhang, Yi; Zhou, Hu; Jiang, Zhongxing; Wu, Dengshu; Zhuang, Junling; Li, Wei; Jiang, Qian; Wang, Xiuli; Huang, Jinwen; Zhu, Huanling; Yang, Linhua; Du, Xin; Li, Fei; Xia, Ruixiang; Zhang, Feng; Hu, Jianda; Li, Yan; Hu, Yu; Liu, Jing; Jin, Chenghao; Sun, Kai; Zhou, Zeping; Wu, Liqing; Yu, Wenjuan; Jin, Jie (December 2022). "Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naïve patients with myelofibrosis: Results of a phase II trial". American Journal of Hematology. 97 (12): 1510–1519. doi:10.1002/ajh.26709. ISSN 1096-8652. PMC 10092883.
- ^ Zhang, Yi; Zhou, Hu; Xiao, Zhi-Jian; Duan, Minghui; Gao, Sujun; He, Guangsheng; Jing, Hongmei; Li, Junmin; Ma, Liangming; Zhu, Huanling; Chang, Chunkang; Du, Xin; Hong, Mei; Li, Xin; Liu, Qingchi; Wang, Wei; Xu, Na; Yang, Haiping; Zhao, Qingwei; Jin, Jie (2023). "Jaktinib in patients (pts) with myelofibrosis (MF) who were intolerant to ruxolitinib (RUX): An open-label, single-arm phase 2b study". Journal of Clinical Oncology. 41 (16_suppl): 7061–7061. doi:10.1200/JCO.2023.41.16_suppl.7061.